Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Probi AB (publ)
  6. News
  7. Summary
    PROB   SE0001280355

PROBI AB (PUBL)

(PROB)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Probi : New clinical results on stress from Probi and their probiotic strain L. plantarum, HEAL9

08/27/2020 | 09:01am EDT

Randomized, double blind, placebo-controlled clinical study published. The trial showed significant reduction in the pro-inflammatory markers fractalkine and CD163.

Maintaining or improving mental health and function is of growing interest for many people, and the number of chronically stressed people is increasing dramatically. Mental health is an area which is addressed by the World Health Organization (WHO)*, as it has great impact on individuals as well as on our society in general.

Probiotics may play a role for psychological function, as the intestine and the brain are connected via the gut-brain axis. Furthermore, the intestinal microbiota influences the immune activation and signaling molecules that are involved in the stress response.

During acute stress the immune system is activated, leading to an imbalance between inflammatory and anti-inflammatory responses. In chronic stress this imbalance and resulting low-grade inflammation may lead to development of diversified stress-related diseases such as cardiovascular diseases, neurodegenerative diseases and cancer.

"The aim of the study was to investigate if intake of the probiotic strain Lactiplantibacillus plantarum, HEAL9[TM] could counteract elevated cortisol and inflammation levels in subjects with chronic stress that are exposed to an acute stress test", explains Titti Niskanen, Director R&D & Clinical Operations.

"We are pleased with the clinical results showing that intake of Lactiplantibacillus plantarum, HEAL9[TM] resulted in significantly decreased plasma levels of the two inflammatory markers (soluble fractalkine and CD163) compared to placebo - these markers are coupled to acute stress in chronically stressed individuals", Niskanen concludes. It is, to our knowledge, the first time it has been shown that acute mental stress triggers the immediate release of soluble fractalkine but also that a probiotic intervention can reduce the release and thereby potentially mitigate the negative physiological side effects of stress.

Tom Rönnlund, CEO at Probi emphasizes the clinical importance of probiotics and mental health: "We are very excited about the study results with HEAL9[TM]", and he continues: "Probi believes that probiotics can play a part in mental health and improve the well-being of many people. This exploratory study provides us with a good platform for further investigations within the gut-brain axis area".

The clinical trial, published in Physiology & Behavior, can be found here (https://doi.org/10.1016/j.physbeh.2020.113083).

 

FOR FURTHER INFORMATION, CONTACT:

Charlotte Beyerholm, Director Marketing & Global Communication, Probi[®], tel +46 76 870 94 65, e-mail: charlotte.beyerholm@probi.com
Titti Niskanen, Director R&D & Clinical Operations, Probi, tel +46 46 286 89 68, e-mail: titti.niskanen@probi.com
Tom Rönnlund, CEO, Probi[®], tel +46 46 286 89 40, e-mail: trd@probi.com

 

ABOUT PROBI

Probi is a world leader within probiotics. Our vision is to help people live healthier lives by delivering effective and well-documented probiotics, with proven health benefits based on scientific research. Probi offers dedicated probiotic expertise and partnership all the way from R&D to finished products for companies within the consumer healthcare and food industry. Our GMP certified manufacturing facilities produce probiotics in custom made formats with value-adding delivery technologies. Founded by scientists in Sweden 1991, Probi is a multinational company with 4 centers of excellence, active in more than 40 markets around the world and holding over 400 patents worldwide. Read more at www.probi.com.

* Reference: https://www.who.int/mental_health/evidence/en/Note: Lactiplantibacillus plantarum was formerly named Lactobacillus plantarum, prior to the taxonomic reclassification.

 

[image]  

https://news.cision.com/probi/r/new-clinical-results-on-stress-from-probi-and-their-probiotic-strain-l--plantarum--heal9-tm--,c3182604

https://mb.cision.com/Main/1556/3182604/1298420.pdf

https://news.cision.com/probi/i/gettyimages-1188480338-stress-publication,c2818055

(c) 2020 Cision. All rights reserved., source Press Releases - English

Stocks mentioned in the article
ChangeLast1st jan.
PROBI AB (PUBL) 8.62% 605 Delayed Quote.31.99%
SYMRISE AG 0.94% 117.6 Delayed Quote.7.47%
All news about PROBI AB (PUBL)
06/15PROBIá : and Oriflame enter partnership for digestive...
PU
06/15PROBIá : and Oriflame enter partnership for digestive probiotic concept launch
AQ
05/31PROBIá : Improved probiotic products for women's health - an unmet market need
AQ
05/31PROBIá : Change in the number of shares and votes in Probi
AQ
05/31PROBIá : Improved probiotic products for women's health – an unmet...
PU
05/10PROBI AB (PUBL) : Ex-dividend day for final dividend
FA
05/07PROBIá : Annual General Meeting 2021
AQ
04/23Q1 2021 : Good growth in the first quarter
AQ
04/22PROBIá : and China National Pharmaceutical Foreign Trade Corporation have signed..
AQ
04/21PROBIá : Iron status in healthy pregnant women improved by the probiotic Probi F..
AQ
More news
Financials
Sales 2021 758 M 89,5 M 89,5 M
Net income 2021 119 M 14,0 M 14,0 M
Net cash 2021 318 M 37,5 M 37,5 M
P/E ratio 2021 57,3x
Yield 2021 0,27%
Capitalization 6 802 M 803 M 803 M
EV / Sales 2021 8,55x
EV / Sales 2022 7,47x
Nbr of Employees -
Free-Float 36,4%
Chart PROBI AB (PUBL)
Duration : Period :
Probi AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PROBI AB (PUBL)
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
 
Mean consensus -
Number of Analysts 2
Last Close Price 597,00 SEK
Average target price 505,00 SEK
Spread / Average Target -15,4%
EPS Revisions
Managers and Directors
NameTitle
Tom Juhani R÷nnlund Chief Executive Officer
Henrik Lundkvist Chief Financial Officer
Jean-Yves Parisot Chairman
Niklas Brandt Vice President-Information Technology
Niklas Larsson Lead Scientific Affairs
Sector and Competitors
1st jan.Capitalization (M$)
PROBI AB (PUBL)31.99%748
NESTLÉ S.A.10.93%355 139
MONDELEZ INTERNATIONAL, INC.6.60%89 301
YIHAI KERRY ARAWANA HOLDINGS CO., LTD-18.01%74 370
THE KRAFT HEINZ COMPANY15.81%49 097
DANONE6.03%44 310